What this trial means for you
This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Retatrutide for obesity, overweight.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Have a Body Mass Index (BMI) at screening * ≥ 30 kilogram per square meter (kg/m2) OR * ≥ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease * Have at least one unsuccessful attempt to lose weight by dieting Exclusion Criteria: * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have type 1 diabetes or type 2 diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening: * heart attack * stroke * hospitalization for unstable angina or heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening
Study sites by state
Arizona
- Arizona Research Center — Phoenix
California
- Care Access - Huntington Beach — Huntington Beach
- Los Angeles Institute for Metabolic Research — Los Angeles
Florida
- New Horizon Research Center — Miami
- Encore Medical Research - Weston — Weston
Hawaii
- Pacific Diabetes & Endocrine Center — Honolulu
Kentucky
- Monroe Biomedical Research - Louisville — Louisville
Massachusetts
- Brigham and Women's Hospital Diabetes Program — Boston
Michigan
- Great Lakes Research Group, Inc. — Bay City
New York
- NYC Research INC — Long Island City
- Weill Cornell Medical College — New York
North Carolina
- Care Access - Raleigh — Raleigh
Tennessee
- New Phase Research and Development — Knoxville
Texas
- Velocity Clinical Research, Dallas — Dallas
- Cedar Health Research - Texas Native Health — Dallas
- Cedar Health Research — Dallas
- Cedar Health Research - Fort Worth — Fort Worth
Utah
- Advanced Research Institute — Ogden
Virginia
- Dominion Medical Associates, Inc. — Richmond
West Virginia
- CAMC Institute for Academic Medicine — Charleston
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)